Compare Diamondback Energy Inc (FANG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Novartis AG — how do they compare? Diamondback Energy Inc trades at $190.3 (market cap $53.38B), while Novartis AG trades at $151.48 (market cap $287.66B). The key difference: Novartis AG is far larger — about 5.4× Diamondback Energy Inc's market cap, and Novartis AG pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| FANG | NVS | |
|---|---|---|
Market Cap | $53.38B | $287.66B |
Sector | Energy | Health |
52-Week High | $213.69 | $168.62 |
52-Week Low | $134.53 | $113.50 |
Enterprise Value | $67.11B | $327.68B |
Dividend Yield | 2.32% | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $190.69, showing slight daily weakness but maintaining a bullish technical outlook with strong analyst support. The company demonstrates solid revenue growth reaching $14.93B in 2025, though net margins have compressed to 1.88%. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 missed, with Q2 2026 results pending. The stock benefits from overwhelming analyst consensus with 90% buy ratings and a $234.50 price target representing 23% upside potential.
FANG presents a compelling growth story with expanding operations and strong cash generation, though investors face margin compression risks amid volatile energy markets. The stock's elevated P/E ratio of 193.63 reflects growth expectations, while technical indicators suggest near-term support around $189. Institutional sentiment remains positive with upcoming Q2 earnings on August 3, 2026, serving as the next key catalyst.
Novartis (NVS) trades at $150.36, down 1.96% with bearish technical signals. The company maintains strong profitability with 75.38% gross margins and 23.92% net income margin, though recent earnings show mixed results with one beat and two misses. Recent acquisitions including Myricx Bio for up to $1.5 billion expand the oncology pipeline, while regulatory approvals for Itvisma and positive drug trial data support growth prospects.
While analyst consensus leans cautious with 68% hold ratings, Novartis' robust cash flow generation and strategic pipeline investments provide long-term value. Key risks include execution challenges from recent acquisitions and competitive pressures in pharmaceuticals. The stock offers stability through strong fundamentals but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
